To enable pooled analyses of continuing and planned randomised trials of prostate cancer screening, guidelines for minimal data required for such analyses were developed in the recent meeting of the International Prostate Screening Trial Evaluation Group (IPSTEG).
Summary
To enable pooled analyses of continuing and planned randomised trials of prostate cancer screening, guidelines for minimal data required for such analyses were developed in the recent meeting of the International Prostate Screening Trial Evaluation Group (IPSTEG).
The aim of the pooled analysis with data on individual level will be: (a) Estimation of the effect ofscreening on prostate cancer mortality with greater precision than individual studies (b) Assessment of optimal screening procedures and interval (c) Identification of subgroups within the populations that might receive most benefit from screening (el) Evaluation of the quality of life effects and cost effectiveness of screening.
All studies included in the combined analysis share a common core protocol with minimum data requirements. The protocol allows, however, adaptation of the procedures to local circumstances within defined options.
It should be noted that the process is continuing and the protocol is subject to evaluation and revision in the meetings of the IPSTEG on a regular basis. (Journal of Medical Screening 1996; 3:97-104) Key words: prostate cancer, prostate specific antigen, pooled analysis.
The public health importance of prostate cancer is illustrated by the fact that together with lung cancer it is the most common cancer type among men in most industrialised countries. In 1985 its age standardised (world standard population) incidence ranged from 70 to 150 per 100000 per year in North America and from 20 to 70 per 100 000 in Europe. 1 Prostate cancer mortality in 1985 ranged from 10 to 20 per 100 000 per year in North America and in Europe. It is most common in North America (especially among black subjects) and in northern Europe. In these countries the incidence is increasing by 10-30% every five years. 1 2 Mortality is also increasing, but less rapidly.
Within the target age group for prostate cancer screening (50-70 years), the incidence is much higher (from 100 to 150 per 100 000 per year). The lifetime risk of prostate cancer among these men is about 6-8%, and risk of death due to prostate cancer 2-5%.
Prospects for control of prostate cancer Because the cause of prostate cancer is poorly understood, prospects for primary prevention of prostate cancer are not promising, though there is some optimism about chemoprevention.' As advanced prostate cancer is not curable the most feasible way to control it is through early detection and treatment achieved by screening. So far, the attempts using digital rectal examination have not been very encouraging." 5 Transrectal ultrasound may have equal or better properties as a screening test, but its use is limited by high costs." 7 Combination of the two methods does not considerably improve the effectiveness of screening." In recent years the potential of serum prostate specific antigen (PSA) as a screening tool has gained increasing interest. Prostate specific antigen has been shown to have equal or better sensitivity, specificity, and positive predictive value than digital rectal examination or transrectal ultrasound; and it has an area under the receiver-operator characteristic curve of 88 %.10 Among asymptomatic men a sensitivity as high as 81 % for a cut off level of 4.0 ug/l has been reported, and the corresponding positive predictive value was 33%.10 Prostate specific antigen has been combined with other tests in order to maximise the sensitivity and specificity. However, so far, the best combination of screening tests remains unclear. Preliminary results suggest that the screen detected cancers are more often confined to a single organ and are equally well or better differentiated than spontaneously detected cancers.":"
A high prevalence of indolent prostate cancer at necropsy as well as in cystoprostatectomy and transurethral resection specimens has led to fears of overdiagnosis and subsequent overtreatment due to prostate cancer screening and possible adverse net effect among screened men. 14 Still there is little doubt that a large proportion of locally confined prostate cancers will progress, which is a real threat to men in the screening ages with an expected lifetime of 10-20 years." 15 This view is further supported by the findings that half of the Tic tumours detected by serum PSA were locally advanced. 16 Prospective evaluations based on serum banks showed that serum PSA enables the detection of prostate cancer several years before the clinical phase and suggested that the promising preliminary results are not attributable to overdiagnosis. 17 -22 It has been recognised that conclusive evidence for the value of screening can only be obtained from randomised screening trials." 2. Large trials are extremely expensive and cannot easily be financed in one European country. To show a reduction in mortality of 20% the expected overall number of prostate cancer deaths required is 1270, given a significance level of 0.05 (two sided) and power of 0.90.0 5 This means that if mortality from other causes is 30 per 1000 per year (mean over follow up time) and mortality from prostate cancer 70 per 100 000 per year, at least 190 000 men (with 1:1 randomisation) would have to be enrolled in the ages 55-69 to show a mortality reduction of 20% in 15 years of follow up. However, any contamination (screening in the control group) will reduce the power. Given the high mortality from prostate cancer, even a mortality reduction of 10% would lead to a considerable public health impact as it would mean seven prevented deaths per 100 000 men per year in these age groups. In the future the public health importance will become even more pronounced as the size of the population in the age groups relevant for prostate cancer screening increases.
Thus evidence will have to be collected from several smaller randomised trials, the results from which will be analysed jointly using individual data. To facilitate this process an international evaluation group has been formed of researchers in Europe and North America. All the members have a continuing or planned randomised trial on the subject, and the international group also welcomes all interested parties with appropriate plans. The purpose of the evaluation group is to develop a prospective evaluation plan for the eventual joint analysis of data from the various trials, which is vital for the success of the enterprise. By preparing the minimum requirements in advance, the comparability of the studies can be maximised and, hence, some of the weaknesses of retrospective meta-analysis should be overcome (including differences in study design and intervention, as well as lack of publication bias). It is also hoped that studies yet to be started might meet the requirements. Furthermore, surveillance of the continuing studies will identify deviations from the common core protocol and, if necessary, adjustments will be made during the course of the studies.
Aim of the comblned analysis
Hypotheses to be tested should start from the key question: can prostate cancer screening reduce mortality from prostate cancer? To answer this question a strictly uniform design would provide most power. However, variability in design between studies offers some important advantages. In addition to an overall estimate of the effect, a pooled analysis may -unlike any of the current or planned individual trials -also be able to provide answers to more specific questions, such as what would be the best screening procedure and rescreen interval, what subgroups of the population might benefit most from screening (for example, certain age groups, persons with Auvinen, Rietbergen, Denis, Schroder, Prorok other risk factors). Efficacy trials based on recruitment of volunteers (who may have increased risk of prostate cancer) may indicate the maximum effect. Population based studies give estimates of what would be the effect of screening the general population as part of routine health care.
Alongside a common core protocol, there is variation in the study design between different groups (table 1) . For instance, the cut off value for a screen positive finding varies from 2 to 4 ug/l, the screening procedure may include digital rectal examination or transrectal ultrasound, or both, in addition to determination of serum PSA concentration, and the screening interval ranges from one to four years. To a degree, variability between the substudies is an asset that enables comparison of different features in the screening protocol and give clues to the best strategy for prostate cancer screening, most importantly the screening procedures, screening interval, and age groups. However, the statistical power may not be adequate for formal evaluation of these features. For which issues and to what extent variability is desirable and acceptable depends on the questions the common analysis seeks to answer. The common core protocol should be retained and variability must not under any circumstances form an obstacle to reaching the major end point. An evaluation of these issues is only feasible, however, given no bias from differences in quality of screening procedures, follow up, and contamination. Table 2 outlines the minimum data set for the joint analysis. Additional study centres fulfilling the minimum requirements may be included in the joint analysis. Also, these criteria will be used for monitoring the implementation of the study protocol in each country.
An essential part of the trials is the quality of life evaluation, assessing the effects of screening and diagnostic procedures, the effect of detection of cancer at an earlier age, and treatment related morbidity. This will be a crucial feature in the overall evaluation of harms and benefits.
Cost effectiveness and cost-benefit analysis must also be performed before prostate cancer screening can be widely implemented. A decision tree to be used as a basis of all cost effectiveness analyses is planned.
A number of side studies are being considered relating to cause, treatment, and prognosis of prostate cancer. For this purpose, biorepositories including serum, whole blood or lymphocytes and/or prostate tissue are planned. These are not included in the minimum requirements.
Prospective evaluation plan
The primary end point of the trials is mortality from prostate cancer. Assessment of quality of life effects and cost efficiency and cost-benefit analyses are also of critical importance. Intermediate end points may also be used, but need to be carefully designed and will have limited value. Intermediate end points may include: (a) Properties of the screening procedure (rate of screening positive findings and cancer 
STUDY POPillAnON
The study population for a trial may be based on a defined segment of the population identi-fied from a population registry (in a population based trial) or recruitment of volunteers through mass media or personal contact such as direct mail (in an efficacy trial). Eligibility criteria include recruitment at the ages 55-67, but a wider age range at entry is also possible. Currently, men are recruited in some studies from age 50 up to 74. As baseline characteristics, information on history of previous prostatic disease and its treatment as well as previous prostate cancer screening will be collected at entry.
Minimum requirements include exclusion of all men with a previous diagnosis of prostate cancer. Some studies also list diagnosis of prostate hyperplasia with or without surgical (including transurethral resection) or medical treatment (especially finasteride, which decreases serum PSA concentration) and/or previous PSA testing (for example, more than once in the past three years) as exclusion criteria.
Randomisation should be unaffected by the subject's and the randomiser's characteristics or preferences. Thus, for this purpose, computer based randomisation is recommended. Randomisation may be performed with or without stratification by, for example, region, age, or other characteristics. However, randomisation at individual rather than group level is required. Most studies randomly allocate subjects to the intervention and control arms in equal numbers, but other approaches are also feasible as long as they do not cause any difficulties for comparison of the screening and control groups. Randomisation may be carried out either before (in population based trials) or after obtaining an informed consent (in efficacy trials).
The participation rate should be reasonably high to maximise power and minimise .the possibility of selection bias. To measure potential bias the comparability of risk factor distribution between the arms, and also between participants and non-participants should be assessed.
The control group may be offered some other type of intervention, unrelated to prostatic disease, or no intervention. Delayed screening of the control group is not recommended, because it interferes with comparison of the screening and control groups. This is especially important as mortality reduction may appear only 10 or more years after screening. Interaction with the control group should be minimised to avoid contamination. It should be noted that currently there is insufficient evidence for the beneficial effects of prostate cancer screening, and thus screening cannot be recommended, except for research purposes. The degree of contamination should be assessed at baseline and during the course of the study, at least from a sample of the men in the control arm.
Collection of information on exclusion criteria in the control group for trials with randomisation before consent is included in the minimum requirements. Additionally, information on baseline characteristics, such as previous PSA screening, history of prostatic disease and treatment received, is suggested. High prevalence of screening in the control group decreases the power of the study and may render a study ineligible for joint analysis. Quality oflife evaluation in the control group is encouraged. Figure 1 outlines the screening algorithm. Determination of serum PSA concentration will be the principal screening method and performed independently of other possible screening proceduresthat is, the feasible combinations include PSA alone; PSA and digital rectal examination; and PSA combined with both digital rectal examination and transrectal ultrasound. This decision was based on recent results indicating that use of PSA density, PSA velocity or age referenced PSA does not improve the performance of the screening test.":" Contrasting results recommending the use of age specific cut off levels have also been reported, based on healthy men and material obtained from a serum bank study," 30 They were, however, not considered as relevant as those obtained from a screening setting with a limited age range of subjects.
SCREENING PROCEDURE
The screening procedure is based on a monoclonal PSA assay. Hybritech Tandem-E has a very good performance and was chosen as the standard assay for the European randomised study of screening for prostate cancer and for the prostate, lung, colorectal, and ovarian screening trial of the National Cancer Institute in the USA. 13 31 The cut off level varies between 2.0 and 4.0 ug/l in different trials. All men with a positive PSA test will be referred for diagnostic examinations irrespective of the digital rectal examination or transrectal ultrasound findings. With a PSA cut off level of 4.0 Ilg/1 the proportion of men screening positive is expected to be about 8-14%.9 10 12 The positive predictive value for PSA of 4.0 l!g!l or above has been 30-33% among asymptomatic men.' 10 32 This means that two out of three men screening positive will not have prostatic cancer. The expected detection rate in the first screening round is about 3%. 13 Incorporation of other, additional screening tests such as digital rectal examination or transrectal ultrasound to the screening procedure is encouraged to improve the sensitivity." This may, however, increase the rate of false positive findings. If additional tests are used for all men in the screening arm, all men with PSA above the cut off level will be regarded as screening positive. In addition, abnormal findings in other testes) even in the presence of a normal PSA concentration may be defined as a screen positive finding. Also, a stepwise screening protocol may be used with further examinations among men with a PSA concentration approaching the cut off level -for example, digital rectal examination or transrectal ultrasound, or both, may be used as confirmatory examinations for men with PSA concentrations The optimum treatment of early, clinically localised prostate cancer is not known, as randomised trials comparing radical prostatectomy, radiotherapy, and expectant management have not been conducted." Therefore, no uniform treatment schemes can be implemented in the trials.
Treatment of prostate cancer must follow the same guidelines in both randomised groups -that is, patients with similar characteristics should be offered similar treatment options. Also, treatment should be in accordance with the general principles and practice at the time of diagnosis. At the least, coordination within the study region is required so that identical treatment guidelines and quality assurance are adopted for all hospitals in charge of treatment in the study population. As far as possible, the treatment should be standardised by centralisation of patients with prostate cancer from both groups to the same hospital(s).
Similarly, standardisation of pathological review and reporting is recommended.
Auoinen, Rietbergen, Denis, Schroder, Prorok FOLLOW UP Follow up for cancer incidence through population based cancer registries is required for assessing the occurrence of interval cancers, and also for estimating the sensitivity. Data on cancer incidence in this fashion are available for most, though not all, study groups.
Follow up for cancer mortality should be complete: at least 95% for both vital status and cause of death ascertainment is required. It can be either active (based on contact with the subjects and/or their relatives or through hospital records) or passive through registries. Similar procedures should be followed in both arms of the study to avoid differences in completeness of follow up. Both death certificates and clinical records should be available at least for a random sample of all deaths and of deaths from cancer for review of causes of death. Routine cause of death data may be inadequate for the purposes of the study. By relying on routine data, some loss of power may result from misclassification, but no bias can be expected, given similar follow up.
A cause of death subcommittee will be established for the definition of death from prostate cancer and for review of death certificates and other relevant data.
Owing to the slow growth rate suggested by the natural history of prostate cancer, 10 to 15 years of follow up may be needed until definitive answers about the effect of screening on prostate cancer mortality can be obtained.
POOLED MORTALITY ANALYSIS
The pooled mortality analysis will be conducted along the same lines as the pooled analyses of mammography screening trials." 35 The analysis will be based on the "intention to screen" principlethat is, non-participants and dropouts will be included in the intervention arm and those with screening outside the trial setting in the control group. This is necessary to avoid selection bias. The preliminary analyses will be based on aggregate data aimed at exploring the comparability of the effect of screening by trial, with screening interval and applied screening tests as explanatory variables. The final analyses will be based on individual data from trials eligible for pooled analysis. The Cox model for cohort analysis will be applied with stratification by trial, age at first screening round, and number of screening rounds.
OTHER END POINTS
Quality of life evaluation is not included in the minimum requirements, but its importance for the final decision about implementation of prostate cancer screening as a part of the routine health care is recognised. Quality oflife assessment should cover both overall and genitourinary specific issues of health related quality of life. Comparable approaches and instruments in different studies should be used to allow combined analyses. Of the generic instruments, for example, the MOS 36 item short form health survey (SF-36),'" and of cancer specific instruments, the European Organisation for Research and Treatment of Cancer QLQ-C30," have been translated and validated in several languages. Quality of life should be assessed at baseline and at intervals during follow up. Both arms (including nonparticipants) should be included if feasible. The sampling from the screening group should cover both men with normal and abnormal screening findings, and screen positive men with and without the diagnosis of prostate cancer. Inclusion of men withprostate cancer from the control group is regarded as very valuable.
Formation of a data monitoring committee is recommended for each trial. One of the main tasks of this committee is to formulate rules for stopping the trial. Interim analyses should be kept to a minimum and carried out according to a prespecified plan.
Conclusion
Common analysis of randomised prostate cancer screening trials offers advantages, most important of which include increased statistical power and the possibility of obtaining sufficient data for reliable evaluation more quickly than in a single study.
An international group aiming at enabling such analysis has been founded, and new members are invited to join.
The effect ofPSA screening on prostate cancer mortality is currently unknown. The use of PSA screening is not encouraged except within soundly designed trials until it has been shown that: (a) It is capable of reducing prostate cancer mortality (b) It does not have major detrimental effects on quality of life (c) It is cost efficient. These effects are not expected to be shown until 10 to 15 years from now.
